clavis

Also found in: Encyclopedia, Wikipedia.

clavis

(ˈkleɪvɪs; Latin ˈklɑːwɪs)
n
1. a key
2. a glossary
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Mentioned in
References in periodicals archive
19 August 2010 - Norwegian cancer drug developer Clavis Pharma ASA (OSL: CLAVIS) said Wednesday it has recruited the first patient in its pivotal phase III study assessing its lead product elacytarabine in patients with late-stage acute myeloid leukaemia (AML).
Norwegian Clavis Pharma recruits first patient in pivotal AML trial
M2 EQUITYBITES-August 19, 2011--DnB NOR sees promising future for Clavis Pharma's candidate elacytarabine(C)2011 M2 COMMUNICATIONS http://www.m2.com
-DnB NOR sees promising future for Clavis Pharma's candidate elacytarabine
6 August 2010 - Norwegian cancer drug development company Clavis Pharma (OSL: CLAVIS) and its US partner Clovis Oncology Inc said today that the first two patients have been recruited into a Phase II clinical study comparing CP-4126 (also known as CO-1.01) with gemcitabine in the treatment of patients with pancreatic cancer.
Clavis Pharma, Clovis Oncology announce first patients recruitment in Phase II CP-4126 study
NORDIC BUSINESS REPORT-17 June 2010-Investtech rates "buy" on Norwegian Clavis Pharma(C)1994-2010 M2 COMMUNICATIONS http://www.m2.com
Investtech rates "buy" on Norwegian Clavis Pharma
30 April 2010 - Norwegian cancer drug development company Clavis Pharma ASA (OSL: CLAVIS) said today that it has inked a licence agreement with Ventana Medical Systems Inc, a wholly owned member of the Roche Group (VTX: ROG), providing Ventana with exclusive access to Clavis Pharma's monoclonal antibody targeting human nucleoside transporter 1 (hENT1) and to the hybridoma cell line that produces the antibody.
Clavis Pharma licenses rights to hENT1 antibody to Ventana
23 April 2010 - Norwegian cancer drug developer Clavis Pharma ASA (OSL: CLAVIS) said yesterday its partner for the CP-4126 drug candidate, Clovis Oncology Inc has signed a contract to develop and commercialise the hENT1 companion diagnostic with US firm Ventana Medical Systems.
Clavis Pharma's partner signs development deal for CP-4126 companion diagnostic
23 April 2010 - Norwegian cancer drug developer Clavis Pharma said yesterday its partner for the CP-4126 drug candidate, Clovis Oncology Inc, has signed a contract to develop and commercialise the hENT1 companion diagnostic with US firm Ventana Medical Systems.
Clavis Pharma says partner gets development deal from Ventana Medical Systems
NORDIC BUSINESS REPORT-17 February 2010-Norwegian Clavis Pharma Q4 '09 net loss narrows to NOK24.3m(C)1994-2010 M2 COMMUNICATIONS http://www.m2.com
Norwegian Clavis Pharma Q4 '09 net loss narrows to NOK24.3m
M2 EQUITYBITES-May 5, 2011--Norwegian Clavis Pharma after-tax loss expands in Q1 2011(C)2011 M2 COMMUNICATIONS http://www.m2.com
-Norwegian Clavis Pharma after-tax loss expands in Q1 2011
Clavis Pharma (OSL: CLAVIS) got a "buy" rating and a NOK75 target.
DnB NOR reviews stance on healthcare, pharma stocks in Oslo
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.